Progesterone receptor status and tumor grade predict the 21-gene recurrence score of invasive lobular breast cancer

Biomark Med. 2019 Aug;13(12):1005-1012. doi: 10.2217/bmm-2019-0209. Epub 2019 Jun 25.

Abstract

Aim: To assess the association between established clinicopathological variables and the 21-gene recurrence score (RS) stratification of invasive lobular carcinoma (ILC) of the breast. Materials & methods: We identified 9030 ILC patients from the Surveillance, Epidemiology and End Results database. Results: Older age, higher grade tumor and progesterone receptor (PR)-negative disease were independent predictors of high-risk RS stratification. Among patients with PR-positive tumors, 3, 6 and 15% with well-differentiated (G1), moderately-differentiated (G2) and poorly and/or undifferentiated (G3) disease were in the high-risk cohort, respectively. In patients with PR-negative tumors: 16, 24 and 41% of patients with G1, G2 and G3 disease were in the high-risk cohort, respectively. Conclusion: The 21-gene RS testing may not be necessary for patients with PR+/G1-2 ILC.

Keywords: Oncotype DX; SEER; carcinoma; lobular; neoplasm grading; predict factors; progesterone; receptors; recurrence score; risk stratification.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • Carcinoma, Lobular / genetics*
  • Carcinoma, Lobular / metabolism
  • Carcinoma, Lobular / pathology
  • Cohort Studies
  • Female
  • Gene Expression Profiling
  • Humans
  • Middle Aged
  • Neoplasm Grading
  • Receptors, Progesterone / genetics
  • Receptors, Progesterone / metabolism*

Substances

  • Biomarkers, Tumor
  • Receptors, Progesterone